Savara(US:SVRA) Prnewswire·2025-10-13 13:00Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Savara Inc. regarding a class action lawsuit related to misleading statements and omissions concerning the company's drug application for MOLBREEVI, which is intended for treating pulmonary alveolar proteinosis [1][2]. Group 1: Allegations and Class Period - The class period for the allegations is from March 4, 2024, to May 23, 2025 [1]. - Allegations include that Savara's statements about the MOLBREEVI Biologics License Application (BLA) were materially false and misleading, particularly regarding the lack of sufficient information on the drug's chemistry, manufacturing, and controls [1]. - It is claimed that the FDA was unlikely to approve the MOLBREEVI BLA in its current form, which would delay the submission timeline previously communicated to investors [1]. Group 2: Impact on Company and Shareholders - The delay in regulatory approval for MOLBREEVI increases the likelihood that Savara would need to raise additional capital [1]. - Shareholders who purchased shares during the class period are encouraged to register for the class action, with a deadline to seek lead plaintiff status set for November 7, 2025 [2]. - Participants in the class action will be enrolled in a portfolio monitoring software to receive updates on the case [2]. Group 3: Law Firm's Commitment - The Gross Law Firm is recognized for protecting investors' rights against deceit and fraud, emphasizing the importance of responsible business practices [3]. - The firm aims to recover losses for investors caused by misleading statements or omissions that led to artificial inflation of the company's stock [3].